Literature DB >> 3663878

Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.

J G Wagner1, M C Rogge, R B Natale, K S Albert, G J Szpunar.   

Abstract

An aqueous solution containing 1 mg of adinazolam mesylate per ml was administered orally as a single dose (40 mg) and with loading doses followed by hourly doses such that final dose rates of 1, 2, and 3 mg h-1 were administered to steady-state. Four subjects exhibited linear steady-state kinetics, while the other four exhibited Michaelis-Menten kinetics, based on measurement by HPLC of both unchanged drug and the major N-demethyl metabolite. The drug is very rapidly absorbed and has an intrinsic clearance of total (bound + free) drug which averaged 2.14 l min-1 based on the steady-state data and 1.17 l min-1 based on the single dose data, but these means do not differ significantly. The apparent metabolite clearance, CLmc/fm (where fm = fraction of adinazolam converted to the N-demethyl metabolite), averaged 0.170 l min-1 based on steady-state data and 0.179 l min-1 based on single dose data and these means do not differ significantly. Pharmacokinetic parameters, such as these clearances, had large intersubject variations. Three types of bioavailabilities were estimated from the data.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663878     DOI: 10.1002/bdd.2510080502

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

1.  In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate.

Authors:  J W Skoug; M T Borin; J C Fleishaker; A M Cooper
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

2.  Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.

Authors:  J C Fleishaker; J P Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.

Authors:  J C Fleishaker; H Friedman; S R Pollock
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

4.  Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.

Authors:  J C Fleishaker; J P Phillips; T C Smith; R B Smith
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.